Zuba jari zai goyi bayan ayyukan kasuwanci na IALMI™ mai zuwa a cikin Amurka da ƙarin haɓaka bututun asibiti
NEW HAVEN, Conn., Afrilu 19, 2022 (GLOBE NEWSWIRE) - BioXcel Therapeutics, Inc. (NASDAQ: BTAI) ("Kamfani" ko "BioXcel Therapeutics"), wani kamfani da ke amfani da hanyoyin fasaha na wucin gadi don haɓaka matakan kasuwanci na biopharmaceutical. kamfanin canza magunguna a cikin neuroscience da immuno-oncology, a yau ya sanar da wani dabarun kudi yarjejeniya tare da Oaktree Capital Management, LP ("Oaktree") da kuma kudi gudanar da Qatar Investment Authority ("QIA"). A karkashin yarjejeniyar, Oaktree da QIA za su samar. har zuwa dala miliyan 260 a cikin jimlar kuɗi don tallafawa ayyukan kasuwanci na kamfanin IIGALMI ™ (dexmedetomidine) sublingual membrane. Bugu da ƙari, an yi niyyar bayar da kuɗin don tallafawa haɓaka ƙoƙarin haɓaka aikin asibiti na BXCL501, gami da muhimmin shirin Mataki na 3 na babban magani. na tashin hankali a cikin cutar Alzheimer (AD) marasa lafiya, da kuma ƙarin aikin neuroscience na kamfanin da aikin asibiti na immuno-oncology.
Oaktree ne ke jagorantar tsarin dabarun ba da kuɗi na dogon lokaci kuma ya haɗa da abubuwa masu zuwa:
A karkashin yarjejeniyar, BioXcel Therapeutics za ta sami izini daga Hukumar Abinci da Magunguna ta Amurka (FDA) don amfani da samfurin BXCL501 na kamfanin don maganin tashin hankali da ke da alaƙa da schizophrenia ko cutar bipolar I ko II a cikin manya. Afrilu 5, 2022, bin amincewar FDA na IgalMI.
Mahimmin fasali na kuɗin kuɗi sun haɗa da layin bashi na sha'awa-kawai tare da tsawon shekaru biyar da amincewar FDA na BXCL501 don maganin tashin hankali da ke hade da cutar Alzheimer. Layin bashi ya haɗa da babban sassauci ga ci gaban kasuwanci na gaba da abubuwan da suka faru na monetization. , ciki har da BXCL701, kamfanin bincike na baka innate rigakafi activator.A karkashin sharuɗɗan Yarjejeniyar Kudaden Kuɗi na Interest Interest, Oaktree da QIA za su karɓi biyan kuɗin shiga Interest Interest Financing biyan kuɗi, dangane da matsakaicin iyakar dawowa, akan tallace-tallace na IGALMI da duk wani BXCL501 nan gaba. Samfura a cikin Amurka.Haɗin kuɗin shiga ribar kuɗi ya bambanta daga 0.375% zuwa 7.750% na tallace-tallace na shekara-shekara na IGALMI da duk wani samfuran BXCL501 na gaba a cikin Amurka Kuɗi na yarjejeniyar ba da kuɗaɗen riba a ƙananan ƙima a cikin shekaru uku na farko. The dabarun kudi Hakanan ya haɗa da yuwuwar saka hannun jari na kusan dala miliyan 5 a cikin hannun jari na gama gari na kamfani, a zaɓi na Oaktree da QIA, ƙarƙashin yarjejeniyar bashi akan farashin kowane rabo daidai da ƙimar 10% akan ƙimar 30% wanda zai haifar da Oaktree. da/ko QIA don gudanar da zaɓin Matsakaicin nauyin nauyin ƙarar yau da kullun.
Bayan rufe wannan ma'amala, tare da ma'auni na tsabar kuɗi na kamfanin da tsarin kasuwancin da ake tsammanin, BioXcel Therapeutics yana tsammanin samun babban jarin aiki na shekaru masu yawa. Cikakkun aiwatar da wannan tallafin zai ba kamfanin hanyar samun kuɗi zuwa 2025.
"Bayan amincewar da muka yi kwanan nan na IGAALMI da sanarwar bayar da kuɗaɗen yau, ba mu taɓa samun matsayi mafi kyau don gane hangen nesanmu na kasancewa babban kamfanin leken asiri ba," in ji Dokta Vimal Mehta, Shugaba na BioXcel Therapeutics."Mun yi farin ciki da Ƙarfafa matsayin mu na tsabar kuɗi da farko tare da babban jari ba tare da yin la'akari da shi ba yayin da muke shirin ƙaddamar da IGALMI da kuma ci gaba da dabarun haɓaka kayan aikin mu guda uku don wannan ikon mallakar kamfani, wanda ya haɗa da neman ƙarin alamu, fadada isar da mu da kuma fadada tsarin IGAALMI na likita yana samuwa. .A halin yanzu, mun ci gaba da jajircewa don haɓaka ƙarin ilimin kimiyyar ƙwayoyin cuta da ƙwayoyin cuta na rigakafi, gami da BXCL502 da BXCL701."
"Muna farin cikin haɗin gwiwa tare da BioXcel Therapeutics a wannan lokacin mai zuwa na ci gaban da ake sa ran, musamman amincewa da kwanan nan da kuma ƙaddamar da kasuwanci na IGALMI a matsayin babban magani ga tashin hankali da ke da alaƙa da schizophrenia babba ko rashin lafiya na I ko II," in ji Aman Kumar, Co. Manajan Fayil na Oaktree Life Sciences Lending. "Kamfanin yana da ban sha'awa, hanyar AI-kore don gano magunguna da haɓakawa, kuma muna fatan bayar da tallafin faɗaɗa waɗannan ƙoƙarin da kuma taimaka wa kamfanin wajen kawo sabbin jiyya ga marasa lafiya a kusa. duniya."
An tsara ƙarin bayani game da dabarun kuɗaɗen dabarun a cikin Form na BioXcel Therapeutics' Form 8-K yin rajista tare da Hukumar Tsaro da Musanya ta Amurka (SEC).
IGALMI (dexmedetomidine) fim ɗin sublingual, wanda aka fi sani da BXCL501, wani nau'in fim ɗin narkar da baki ne na dexmedetomidine wanda aka nuna don tsananin kula da marasa lafiya tare da schizophrenia ko cuta ta bipolar ƙarƙashin kulawar mai ba da lafiya Tashin hankali na manya da ke da alaƙa da nau'in I ko II cuta. A ranar 5 ga Afrilu, 2022, Hukumar Abinci da Magunguna ta Amurka (FDA) ta amince da IGAALMI dangane da bayanai daga mahimman bayanai guda biyu bazuwar, makafi biyu, sarrafa wuribo. , parallel-group Phase 3 gwajin kimanta IGAALMI don m magani Agitation hade da schizophrenia.SERENITY I) ko bipolar I ko II cuta (SERENITY II).
BioXcel Therapeutics, Inc. kamfani ne na biopharmaceutical ta amfani da hanyoyin hankali na wucin gadi don haɓaka magunguna masu canzawa a cikin ilimin kimiyyar ƙwaƙwalwa da immuno-oncology. Tsarin sake sabunta magungunan na kamfanin yana ba da damar ƙwararrun ƙwararrun da aka yarda da su da / ko ƙwararrun ƴan takarar samfuran asibiti da manyan bayanai da na'ura ta mallaka. koyo algorithms don gano sababbin alamun warkewa. Samfurin kasuwancin kamfanin IGALMI (wanda aka haɓaka a matsayin BXCL501) shine tsarin fim ɗin dexmedetomidine sublingual na mallakar mallaka wanda FDA ta amince da shi don maganin tashin hankali da ke da alaƙa da schizophrenia ko bipolar I ko II cuta a cikin manya .BXCL501 kuma ana kimantawa don maganin cutar Alzheimer mai tsanani, kuma a matsayin magani mai mahimmanci ga babban rashin tausayi. Kamfanin kuma yana haɓaka BXCL502, magani mai mahimmanci don damuwa mai tsanani a cikin lalata, da kuma BXCL701, wani bincike, mai sarrafa na'ura na na'ura mai kwakwalwa, don maganin ciwon daji na prostate mai tsanani da kuma ciwace-ciwacen ciwace-ciwace, wadanda suke da hanawa ko rashin magani.Don ƙarin bayani, ziyarci www.bioxceltherapeutics.com.
BofA Securities sun yi aiki a matsayin mai ba da shawara na tsarin kawai ga BioXcel Therapeutics kuma Cooley LLP sun yi aiki a matsayin mai ba da shawara na shari'a ga BioXcel Therapeutics.Sullivan & Cromwell LLP suna aiki a matsayin lauyan doka ga Oaktree da Shearman & Sterling LLP yana aiki a matsayin mai ba da shawara ga QIA.
Oaktree babban kamfani ne mai kula da saka hannun jari na duniya wanda ya kware a madadin saka hannun jari, tare da dala biliyan 166 a cikin kadarorin da ke karkashin gudanarwa har zuwa Disamba 31, 2021. Kamfanin ya jaddada hanyar da za ta dace, mai dacewa da ƙima da haɗarin haɗari ga bashi, daidaito mai zaman kansa, da dukiya. investing.assets and lists stocks.Kamfanin yana da ma'aikata da ofisoshin fiye da 1,000 a cikin birane 20 na duniya. Don ƙarin bayani, ziyarci gidan yanar gizon Oaktree a http://www.oaktreecapital.com/.
Hukumar Kula da Zuba Jari ta Qatar ("QIA") ita ce asusun arziƙi na ƙasar Qatar. An kafa QIA a cikin 2005 don saka hannun jari da sarrafa Asusun ajiyar kuɗi na ƙasa. QIA tana saka hannun jari a cikin nau'ikan azuzuwan kadara da yanayin ƙasa kuma tana aiki tare da manyan cibiyoyi a duk duniya don gina babban fayil ɗin nau'ikan nau'ikan duniya tare da hangen nesa na dogon lokaci don sadar da ci gaba mai dorewa da ba da gudummawa ga wadatar Qatar.Don ƙarin bayani game da QIA, don Allah ziyarci gidan yanar gizon sa www.qia.qa.
Wannan sakin latsa ya haɗa da "kalmomi masu kallon gaba" a cikin ma'anar Dokar Gyara Shari'a ta Masu zaman kansu ta 1995. Maganganun neman gaba a cikin wannan sakin labaran sun haɗa da, amma ba'a iyakance ga: ƙaddamar da kasuwanci na IGALMI a Amurka don magance tashin hankali a cikin marasa lafiya tare da schizophrenia da cuta na bipolar;tsare-tsaren ci gaban asibiti, ciki har da ci gaba da ci gaban kamfanin na BXCL501, don kula da marasa lafiya da ciwon hauka Agitation kuma a matsayin magani mai mahimmanci ga babban rashin tausayi;tsare-tsaren ci gaban kamfanin na gaba;kudaden da ake tsammani bisa yarjejeniya tare da Oaktree da QIA da kiyasin titin tsabar kudi na kamfanin da kuma sa ran wadatar albarkatun babban kamfanin.Lokacin da aka yi amfani da su a nan, kalmomin da suka haɗa da "tsammaci," "yi," "tsarin," "mai yiwuwa," "mai yiwuwa," "ci gaba," "nufi," "tsara," "manufa," da makamantansu suna nufin A cikin gano maganganun sa ido. Bugu da ƙari, duk wani bayani ko bayani, ciki har da duk wani zato na asali, game da tsammanin, imani, tsare-tsare, hasashe. , manufofin, aiki ko wasu halaye na abubuwan da suka faru na gaba ko yanayi, suna sa ido. Duk maganganun da ake sa ran sun dogara ne akan tsammanin kamfanin na yanzu da kuma zato daban-daban. Kamfanin ya yi imanin cewa tsammaninsa da imani suna da tushe mai ma'ana, amma sun kasance. A zahiri ba tabbas ba.Kamfani na iya zama ba daidai da tsammaninsa ba, kuma imaninsa bazai tabbatar da daidai ba.Sakamako na ainihi na iya bambanta ta zahiri da waɗanda aka bayyana ko kuma suka bayyana ta irin waɗannan maganganun na gaba sakamakon wasu mahimman dalilai, gami da, amma ba'a iyakance ga: Buƙatun Kamfanin na ƙarin babban jari ba da ikonsa na haɓaka jari idan an buƙata;FDA da makamantan hukumomin kasashen waje Tsarin yarda da tsari yana da tsayi, mai ɗaukar lokaci, tsada da rashin tabbas;kamfanin yana da iyakacin ƙwarewa wajen gano magunguna da ci gaban ƙwayoyi;masu mulki ba za su yarda ko yarda da zato, ƙididdiga, ƙididdigewa, ƙididdiga ko nazari na kamfani ba, ko kuma mahimmancin fassara ko auna bayanai ta hanyoyi daban-daban, wanda zai iya shafar ƙimar wani shirin, amincewa ko tallace-tallace na wani takamaiman. dan takarar samfurin ko samfurin da kamfanin gaba ɗaya;kamfanin ba shi da kwarewa a tallace-tallace da sayar da magunguna kuma ba shi da kwarewa tare da IALMI ko BXCL501 tallace-tallace da tallace-tallace;IALMI ko sauran ƴan takarar samfur na Kamfanin ƙila ba za su yarda da likitoci ko ƙungiyar likitocin gabaɗaya ba;Kamfanin na iya kasa samun amincewar tallace-tallace don BXCL501 a Turai ko wasu hukunce-hukuncen;Kamfanin na iya buƙatar ƙarin babban jari don haɓakawa da gudanar da gwaje-gwajen asibiti da ke da alaƙa da ƴan takarar samfurin sa da tallafawa ayyukansu;dole ne kamfanoni su bi ƙa'idodin ƙa'idodi masu yawa;gyare-gyaren kiwon lafiya na iya yin illa ga nasarar kasuwanci a nan gaba. Ana tattauna waɗannan da wasu muhimman abubuwa a ƙarƙashin taken "Abubuwan Haɗari" a cikin Rahoton Shekara-shekara kan Form 10-K na shekarar da ta ƙare Disamba 31, 2021, saboda waɗannan abubuwan na iya bayyana daga lokaci zuwa lokaci. A cikin sauran takardun sa tare da Sabuntawar SEC, da ake samu akan gidan yanar gizon SEC a www.sec.gov.Wadannan da sauran muhimman abubuwa na iya haifar da sakamako na gaske ya bambanta da wanda aka nuna ta bayanan sa ido a cikin wannan sakin labarai. -Maganganun kallon suna wakiltar kididdigar gudanarwa har zuwa ranar da aka fitar da wannan sanarwar.Ko da yake kamfani na iya zaɓar sabunta irin waɗannan maganganun na gaba a wani lokaci a nan gaba, sai dai kamar yadda doka ta buƙata, ya ƙi duk wani takalifi na yin hakan, ko da idan Abubuwan da suka faru na gaba suna sa ra'ayoyinmu su canza. Waɗannan maganganun na gaba bai kamata a yi la'akari da su a matsayin wakiltar ra'ayoyin kamfanin a kowace rana bayan ranar da aka buga wannan sanarwar.
1 Kuɗaɗen kuma ya haɗa da garanti don siyan hannun jari na hannun jari na kamfani da kuma garanti don siyan raka'a na reshen kamfanin LLC, kamar yadda aka kwatanta sosai a cikin rahoton na yanzu kan Form 8-K da za a gabatar a ranar 19 ga Afrilu, 2022.
Lokacin aikawa: Mayu-07-2022